| Literature DB >> 25545217 |
Andreas Wicki1, Dominik Witzigmann2, Vimalkumar Balasubramanian3, Jörg Huwyler4.
Abstract
Cancer is a leading cause of death worldwide. Currently available therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology towards the development of nanomedicine products holds great promise to improve therapeutic strategies against cancer. Nanomedicine products represent an opportunity to achieve sophisticated targeting strategies and multi-functionality. They can improve the pharmacokinetic and pharmacodynamic profiles of conventional therapeutics and may thus optimize the efficacy of existing anti-cancer compounds. In this review, we discuss state-of-the-art nanoparticles and targeted systems that have been investigated in clinical studies. We emphasize the challenges faced in using nanomedicine products and translating them from a preclinical level to the clinical setting. Additionally, we cover aspects of nanocarrier engineering that may open up new opportunities for nanomedicine products in the clinic.Entities:
Keywords: Cancer nanomedicine; Clinical trials; Drug delivery; Liposome; Nanoparticle; Targeting
Mesh:
Year: 2014 PMID: 25545217 DOI: 10.1016/j.jconrel.2014.12.030
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776